natgillin/translations-raw huggingface dataset:
In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (>99.5%), mainly to albumin and α-1-acid glycoprotein.
Študije in vitro v plazmi ljudi, psov, miši in podgan kažejo na visoko vezavo na beljakovine v plazmi (> 99,5 %), pretežno na albumin in α-1 kisli glikoprotein.
Active substance: Telmisartan
Učinkovina: telmisartan
After oral administration, telmisartan is almost exclusively excreted in the faeces mainly as the unchanged active substance.
Po peroralni uporabi se telmisartan izloči skoraj izključno v blatu, pretežno kot nespremenjena učinkovina.
As determined by AUC, food consumption does not affect the overall extent of absorption of telmisartan.
Kot je bilo ugotovljeno z AUC, uživanje hrane ne vpliva na splošni obseg absorpcije telmisartana.
Due to the combination of these pharmacodynamic properties, telmisartan is an appropriate treatment for cats with concomitant hypertension and CKD.
Zaradi kombinacije teh farmakodinamičnih lastnosti je telmisartan primeren za zdravljenje mačk s sočasno hipertenzijo in KBL.
If SBP is below the target or if there are concurrent signs of hypotension, please refer to section 4.5.
Če je SBP pod ciljno vrednostjo, ali če sočasno obstajajo znaki hipotenzije, glejte poglavje 4.5.
Do not use during pregnancy or lactation (see also section 4.7).
Ne uporabite v obdobju brejosti ali laktacije (glejte tudi poglavje 4.7).
EXP {month/year} Once opened use by ....
EXP {mesec/leto} Odprto zdravilo uporabite do....
The absolute bioavailability after oral administration was found to be 33%.
Ugotovili so, da je absolutna biološka razpoložljivost po peroralnem dajanju 33 %.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na škatli in steklenici po EXP.
Semintra is an oral solution and is well accepted by most cats.
Zdravilo Semintra je peroralna raztopina, ki jo večina mačk dobro sprejme.
Pull the plunger out until the end of the plunger corresponds to the amount needed in ml.
Bat vlecite, dokler konec bata ne ustreza potrebni količini v ml.
Do not use during pregnancy and lactation (see section 4.3).
Ne uporabljajte med brejostjo in laktacijo (glejte poglavje 4.3).
Push down and turn cap to open the bottle.
Zaporko potisnite navzdol in jo obrnite, da plastenko odprete.
Shelf life of the veterinary medicinal product as packaged for sale (30 ml or 100 ml): 3 years.
Rok uporabnosti zdravila v pakiranju za prodajo (30 ml ali 100 ml): 3 leta.
If SBP is below the target or if there are concurrent signs of hypotension, please refer to the “Special warnings” section.
Če je SBP pod ciljno vrednostjo, ali če sočasno obstajajo znaki hipotenzije, glejte poglavje 'Posebna opozorila'.
EXP {month/year} Once opened use within 6 months.
EXP {mesec/leto} Odprto zdravilo uporabite v roku 6 mesecev.
The glucuronidation resulted in the formation of the 1-O-acylglucuronide metabolite of telmisartan.
Glukuronizacija povzroči nastajanje 1-O-acilglukuronidnega presnovka telmisartana.
See section “Pregnancy and lactation”.
Glejte poglavje "Brejost in laktacija".
The safety and efficacy of telmisartan has not been tested in cats under the age of 6 months.
Varnosti in učinkovitosti telmisartana niso preskusili pri mačkah, starih manj kot 6 mesecev.
The combination of telmisartan with such agents may lead to additive hypotensive effects or may alter renal function.
Kombinacija telmisartana s takimi zdravili lahko privede do aditivnih hipotenzivnih učinkov ali lahko spremeni delovanje ledvic.
Clear, colourless to yellowish viscous solution.
Bistra, brezbarvna do rumenkasta viskozna raztopina.
After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinarian.
Po 4 tednih se lahko odmerek telmisartana pri mačkah s sistoličnim krvnim tlakom (SBP) manj kot 140 mm Hg (pri povečanjih za 0,5 mg/kg) zmanjša po presoji veterinarja.
From in vitro and ex vivo studies with feline liver microsomes it can be concluded that telmisartan is effectively glucuronidated in the cat.
Iz študij in vitro in ex vivo na mikrosomih mačjih jeter je mogoče sklepati, da se telmisartan pri mačkah učinkovito glukuronizira.
The dosing regimen for hypertensive cats with concomitant chronic kidney disease is as described above except that for these cats the recommended minimum effective dose is 1 mg/kg.
Režim odmerjanja za hipertenzivne mačke s sočasno kronično boleznijo ledvic je opisan zgoraj, razlika je le v tem, da je za te mačke priporočeni efektivni najmanjši odmerek 1 mg/kg.
Due to the mode of action of the veterinary medicinal product, transient hypotension may occur.
Zaradi načina delovanja zdravila za uporabo v veterinarski medicini se lahko pojavi prehodna hipotenzija.
The dosage of telmisartan should be reduced if systolic blood pressure (SBP) is consistently lower than 120 mmHg or if there are concurrent signs of hypotension.
Odmerek telmisartana je treba zmanjšati, če je sistolični krvni tlak (SBP) dosledno nižji od 120 mm Hg, ali če obstajajo sočasni znaki hipotenzije.
Due to the mode of action of the veterinary medicinal product, transient hypotension (low blood pressure) may occur.
Zaradi načina delovanja zdravila za uporabo v veterinarski medicini se lahko pojavi prehodna hipotenzija (nizek krvni tlak).
Telmisartan selectively binds to the AT1 receptor and does not show affinity for other receptors, including AT2 or other less characterised AT receptors.
Telmisartan se selektivno veže na receptorje AT1 in ne kaže afinitete za druge receptorje, vključno z receptorji AT2 in drugimi, manj opredeljenimi receptorji AT.
No clinically relevant accumulation was observed following multiple dose administration once daily for 21 days.
Po večkratnem odmerjanju enkrat na dan 21 dni niso opazili klinično pomembnega kopičenja.
Pull the plunger out until the end of the plunger corresponds to your cat´s body weight in kilograms.
Bat vlecite, dokler konec bata ne ustreza telesni masi vaše mačke v kilogramih.
Red blood cell count should be monitored during therapy.
Med zdravljenjem je treba spremljati število rdečih krvnih celic.
In cats with hypertension it is good clinical practice to regularly monitor blood pressure.
Pri mačkah s hipertenzijo je redno spremljanje krvnega tlaka dobra klinična praksa.
Push the plunger to empty the contents of the syringe directly into the mouth of the cat
Potisnite bat, da izpraznite vsebino brizge neposredno v usta mačke…
The receptor binding is long lasting due to the slow dissociation of telmisartan from the AT1 receptor binding site.
Vezava receptorjev je dolgotrajna zaradi počasne disociacije telmisartana z mesta vezave receptorja AT1.
The safety and efficacy of telmisartan in such patients has not been investigated.
Varnost in učinkovitost telmisartana pri teh bolnikih ni bila raziskana.
Hypokalaemia is associated with CKD, however telmisartan does not affect potassium excretion, as shown in the clinical field trial in cats.
S KBL je pogosto povezana hipokaliemija, vendar telmisartan ne vpliva na izločanje kalija, kot so pokazali terenski klinični preskusi pri mačkah.
When using this product in cats with severe kidney disease, it is advisable to monitor renal function (plasma creatinine concentration).
Pri uporabi tega zdravila pri mačkah s hudo ledvično boleznijo je priporočljivo spremljati delovanje ledvic (koncentracijo kreatinina v plazmi).
The syringe fits onto the bottle and has a ml scale.
Brizga se prilega na stekleničko in ima merilno lestvico po ml.
The safety of Semintra has not been established in breeding, pregnant or lactating cats.
Varnost zdravila Semintra v obdobju parjenja, brejosti ali laktacije mačk ni bila ugotovljena.
In a further clinical trial in cats with hypertension a reduction in mean systolic blood pressure was achieved with a dose of 2 mg/kg.
V nadaljnjem kliničnem preskušanju pri mačkah s hipertenzijo je bilo doseženo znižanje povprečnega sistoličnega krvnega tlaka z odmerkom 2 mg/kg.
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, plain.
Farmakoterapevtska skupina: Zdravila z delovanjem na renin-angiotenzinski sistem, antagonisti angiotenzina II, enokomponentna zdravila.
Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.
Zmanjševanje proteinurije, povezane s kronično boleznijo ledvic (KBL) pri mačkah.
Effects associated with stimulation of the AT2 receptor such as vasodilatation, natriuresis and inhibition of inappropriate cell growth are not suppressed.
Učinki stimulacije receptorjev AT2, kot so vazodilatacija, natriureza in zaviranje neustrezne celične rasti niso zavirani.
Marketing authorisation holder and manufacturer responsible for batch release Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
Ime in naslov proizvajalca zdravila, odgovornega za sproščanje serij Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
Benzalkonium chloride Hydroxyethylcellulose Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Maltitol
6.1 Seznam pomožnih snovi benzalkonijev klorid hidroksietilceluloza natrijev hidroksid (za uravnavanje pH) klorovodikova kislina (za uravnavanje pH) maltitol prečiščena voda
Telmisartan is highly lipophilic and has rapid membrane permeability kinetics, which facilitates easy distribution into tissue.
Telmisartan je izjemno lipofilen in ima hitro kinetiko membranske prepustnosti, kar olajša porazdelitev v tkivo.
1 measuring syringe
1 merilna brizga
The combination of agents targeting the RAAS may alter renal function.
Kombinacija zdravil, ki ciljajo na RAAS, lahko spremeni delovanje ledvic.
Shelf life after first opening of the bottle: 6 months.
Rok uporabnosti po prvem odpiranju stične ovojnine: 6 mesecev.
35 ml 1 measuring syringe
35 ml 1 merilna brizga
The initial recommended dose is 2 mg telmisartan/kg body weight (0.2 ml/kg body weight).
Začetni priporočeni odmerek je 2 mg telmisartana/kg telesne mase (0,2 ml/kg telesne mase).
People with hypersensitivity to telmisartan or other sartans/ARBs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na telmisartan ali druge sartane/ARB naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
As known from substances acting on the Renin-Angiotensin-Aldosterone System (RAAS), a slight decrease in red blood cell count may occur.
Kot pri drugih snoveh, ki delujejo na sistem renin-angiotenzin-aldosteronski (RAAS), se lahko število rdečih krvnih celic blago zniža.
The recommended dose is 1 mg telmisartan/kg body weight (0.25 ml/kg body weight).
Priporočeni odmerek je 1 mg telmisartana/kg telesne mase (0,25 ml/kg telesne mase).
For both, Cmax-values, and AUC-values, a dose proportional increase over the dose range from 0.5 mg/kg to 3 mg/kg was observed.
Tako za vrednosti Cmax kot za AUC so opazili z odmerkom sorazmerno povečanje v razponu odmerka od 0,5 mg/kg do 3 mg/kg.
After administration of the veterinary medicinal product, close the bottle tightly with the cap, wash the measuring syringe with water and let it dry.
Po dajanju zdravila za uporabo v veterinarski medicini tesno zaprite stekleničko s pokrovčkom, merilno brizgo operite z vodo in pustite, da se posuši.
No drug-drug interactions are known from available data in cats with CKD for the use of telmisartan and other medicinal products that interfere with RAAS (such as ARBs or ACEis).
Med razpoložljivimi podatki pri mačkah s CKD niso znane nobene interakcije med zdravili pri uporabi telmisartana in drugih zdravil, ki vplivajo na RAAS (kot so ARB ali ACE).
Effects observed at the recommended treatment dose included mild decreases in red blood cell counts.
Učinki, ki so jih opazili pri zdravljenju s priporočenimi odmerki, so vključevali rahlo zmanjšanje števila rdečih krvnih celic.
One HDPE bottle filled with 35 ml.
Ena HDPE-plastenka, napolnjena s 35 ml.
The following mild and transient gastrointestinal signs have rarely been observed in a clinical study (in order of decreasing frequency): mild and intermittent regurgitation, vomiting, diarrhoea or soft faeces.
V klinični študiji so redko opazili naslednje blage in prehodne prebavne znake (po padajoči pogostnosti): blaga in prehodna regurgitacija, bruhanje, driska ali mehko blato.
Effects attributable to the pharmacological activity of the product observed at the recommended treatment dose included reductions in blood pressure and decreases in red blood cell counts.
Učinki, ki jih je mogoče pripisati farmakološki aktivnosti zdravila, in so jih opazili pri zdravljenju s priporočenimi odmerki, vključujejo znižanje krvnega tlaka in znižanje števila rdečih krvnih celic.
In a European clinical field study, adverse events categorised as renal disorder/insufficiency (includes cases of chronic renal failure, elevated creatinine and/or blood urea nitrogen) were recorded in 3.6% of telmisartan-treated cats and 1% of placebo-treated cats.
V evropski klinični študiji so pri 3,6 % mačk zdravljenih s telmisartanom in 1 % mačk, ki so prejemale placebo, zabeležili neželene učinke, ki so bili označeni kot ledvična motnja/insuficienca (vključeni so bili primeri kronične ledvične odpovedi, povišanega kreatinina in/ali dušika sečnine v krvi).
Telmisartan does not exhibit any partial agonist activity at the AT1 receptor.
Telmisartan nima delnega agonističnega učinka na receptorju AT1.
Following oral administration of 1 mg/kg body weight telmisartan to cats, plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax).
Po peroralnem dajanju 1 mg/kg telesne mase telmisartana mačkam je za krivuljo koncentracije v plazmi po času matične spojine značilna hitra absorpcija z največjimi koncentracijami v plazmi (Cmax) doseženimi po 0,5 ure (tmax).
5.2 Pharmacokinetic properties
5.2 Farmakokinetični podatki
Each bottle is closed with an LDPE plug-in adapter and a tamper-proof child resistant closure.
Vsaka plastenka je zaprta z adapterjem iz LDPE, ki se pritisne v plastenko, in za otroke varno navojno zaporko.
Following oral administration of telmisartan to cats, plasma-concentration-time curves of the parent compound are characterised by rapid absorption, with maximum plasma concentrations (Cmax) achieved after 0.5 hours (tmax).
Po peroralnem dajanju telmisartana mačkam je za krivuljo koncentracije v plazmi po času matične spojine značilna hitra absorpcija z največjimi koncentracijami v plazmi (Cmax) doseženimi po 0,5 ure (tmax).
Stimulation of the AT1 receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis, organ remodelling and proteinuria.
Stimulacija receptorja AT1 je odgovorna za patološke učinke angiotenzina II v ledvicah in drugih organih, povezanih z angiotenzinom II, kot so vazokonstrikcija, zadrževanje natrija in vode, povečana sinteza aldosterona in preoblikovanje organa in proteinurija.
In a clinical trial in cats with chronic kidney disease, a reduction in proteinuria was seen within the first 7 days after the start of treatment.
V kliničnem preskušanju z mačkami s kronično boleznijo ledvic so v prvih 7 dneh po začetku zdravljenja opazili zmanjšanje proteinurije.
Telmisartan displaces angiotensin II from its binding site at the AT1 receptor subtype.
Telmisartan izpodrine angiotenzin II z njegovih vezavnih mest na podtipu receptorjev AT1.
Telmisartan is metabolised by conjugation to the glucuronide of the parent compound.
Telmisartan se s konjugacijo presnovi v glukuronid matične spojine.
No pharmacological activity has been shown for the conjugate.
Ugotovljeno je, da konjugat ni farmakološko aktiven.
Stimulation of the AT1 receptor is responsible for pathologic effects of angiotensin II in the kidney and other organs associated with angiotensin II such as vasoconstriction, retention of sodium and water, increased aldosterone synthesis and organ remodelling.
Stimulacija receptorja AT1 je odgovorna za patološke učinke angiotenzina II v ledvicah in drugih organih, povezanih z angiotenzinom II, kot so vazokonstrikcija, zadrževanje natrija in vode, povečana sinteza aldosterona in preoblikovanje organa.
Carton for 30 ml and 100 ml
Škatla za 30 ml in 100 ml
Very limited data are available regarding interactions in cats with hypertension between telmisartan and other medicinal products that lower blood pressure (such as amlodipine) or interfere with the RAAS (such as ARBs or ACEis).
Med razpoložljivimi podatki pri mačkah s hipertenzijo so na voljo zelo omejeni podatki glede interakcij med telmisartanom in drugimi zdravili, ki znižujejo krvni tlak (kot je amlodipin), ali ki vplivajo na delovanje RAAS (kot so ARB ali ACE).
The syringe fits onto the bottle and has a kg-body weight scale.
Brizga se prilega na stekleničko in ima merilno lestvico po kilogramih telesne mase.
Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEis), have been found to affect the unborn child during pregnancy in humans.
Nosečnice morajo biti posebno previdne, da preprečijo stik z zdravilom, saj so ugotovili, da pri ljudeh snovi, ki vplivajo na RAAS, kot so blokatorji angiotenzinskih receptorjev v (ARB) in zaviralci ACE, med nosečnostjo vplivajo na nerojenega otroka.
In a clinical trial in cats with chronic kidney disease, a reduction in proteinuria was seen within the first 7 days after the start of treatment with 1 mg/kg.
V kliničnem preskušanju pri mačkah s kronično boleznijo ledvic je bilo v prvih 7 dneh po začetku zdravljenja z 1 mg/kg ugotovljeno zmanjšanje proteinurije.
During concomitant therapy with amlodipine at the recommended dose for the reduction of proteinuria associated with chronic kidney disease (CKD) in cats no clinical evidence of hypotension was observed.
Med sočasnim zdravljenjem s priporočenimi odmerki amlodipina za zmanjšanje proteinurije, povezane s kronično boleznijo ledvic (CKD) pri mačkah, niso opazili kliničnih dokazov hipotenzije.
Do not use during pregnancy and lactation.
Ne uporabljajte med brejostjo in laktacijo.
One HDPE bottle filled with 30 ml or 100 ml.
Ena HDPE-plastenka napolnjena s 30 ml ali s 100 ml.
Pack size of one plastic bottle filled with 35 ml and one measuring syringe.
Velikost pakiranja je ena plastenka napolnjena s 35 ml in ena merilna brizga.
Separate the dosing syringe from the bottle.
Merilno brizgo ločite od plastenke.
In the event that hypotension does occur, symptomatic treatment, e.g. fluid therapy, should be provided.
V primeru, da pride do hipotenzije, je potrebno simptomatsko zdravljenje, npr. zdravljenje s tekočino.
It is good clinical practice to monitor the blood pressure of cats receiving Semintra which are under anaesthesia.
Spremljanje krvnega tlaka pri mačkah, ki prejemajo zdravilo Semintra in so pod anestezijo, je dobra klinična praksa.
Telmisartan is an orally active and specific angiotensin II receptor (subtype AT1) antagonist which causes a dose-dependent decrease in mean arterial blood pressure in mammalian species including the cat.
Telmisartan je peroralno aktiven specifičen antagonist receptorja angiotenzina II (podtip AT1), ki povzroči od odmerka odvisno znižanje povprečnega arterijskega krvnega tlaka pri vrstah sesalcev, vključno z mačkami.
Pack sizes of one plastic bottle filled with 30 ml or one plastic bottle filled with 100 ml.
Velikost pakiranja je ena plastenka napolnjena s 30 ml ali ena plastenka napolnjena s 100 ml. 1 merilna brizga.
Interaction with other medicinal products and other forms of interaction During concomitant therapy with amlodipine at the recommended dose no clinical evidence of hypotension was observed.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Med sočasnim zdravljenjem s priporočenimi odmerki amlodipina niso opazili kliničnih znakov hipotenzije.
Benzalkonium chloride
Pomožna snov: benzalkonijev klorid
After administration of up to 5 times the recommended dose for 6 months to young adult healthy cats, adverse reactions observed were consistent with those mentioned in section 4.6.
Po dajanju do 5-kratnega priporočenega odmerka 6 mesecev mlajšim odraslim zdravim mačkam so bili opaženi neželeni učinki skladni s tistimi, ki so omenjeni v poglavju 4.6.
During concomitant therapy with amlodipine at the recommended dose, no clinical evidence of hypotension was observed.
Med sočasnim zdravljenjem s priporočenimi odmerki amlodipina niso opazili kliničnih znakov hipotenzije.
One ml contains: Telmisartan
NAVEDBA UČINKOVINE IN DRUGIH SESTAVIN En ml vsebuje: telmisartan
Attach the dosing syringe to the plug-in adapter of the bottle by gently pushing.
Merilno brizgo nežno potisnite in tako priključite na adapter, ki se potisne v plastenko.
Administration of the product at overdose (3 to 5 times of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN; nitrogen containing waste products in the blood).
Dajanje prevelikega odmerka zdravila (3 do 5-kratni priporočeni odmerek 6 mesecev) je povzročilo bistveno znižanje krvnega tlaka, znižanje števila rdečih krvnih celic (učinki, ki se pripisujejo farmakološki aktivnosti zdravila) in zvišanje sečnine (odpadnih snovi v krvi, ki vsebujejo dušik) v krvi.
Bottle for 35 ml
Škatla za 35 ml
Bottle for 30 ml
Plastenka za 30 ml
Carton for 35 ml
Plastenka za 35 ml
Semintra 10 mg/ml oral solution for cats telmisartan
Semintra 10 mg/ml peroralna raztopina za mačke telmisartan
Mild and transient gastrointestinal signs such as vomiting and diarrhoea associated with product administration have been observed commonly in a clinical study.
V klinični študiji so pogosto opazili blage in prehodne prebavne znake, kot sta bruhanje in driska, ki so povezani z dajanjem zdravila.
Administration of the product at overdose (up to 2.5 times the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN).
Dajanje prevelikega odmerka zdravila (do 2,5-kratnega priporočenega odmerka 6 mesecev) je povzročilo bistveno znižanje krvnega tlaka, zmanjšanje števila rdečih krvnih celic (učinki, ki jih je mogoče pripisati farmakološki aktivnosti zdravila) in povišanje sečnine v krvi.
Administration of the product at overdose (3 to 5 times of the recommended dose for 6 months) resulted in marked reductions in blood pressure, decreases in red blood cell count (effects attributable to the pharmacological activity of the product) and increases in Blood Urea Nitrogen (BUN).
Dajanje prevelikega odmerka zdravila (3 do 5-kratni priporočeni odmerek 6 mesecev) je povzročilo bistveno znižanje krvnega tlaka, znižanje števila rdečih krvnih celic (učinki, ki se pripisujejo farmakološki aktivnosti zdravila) in zvišanje sečnine v krvi.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo V primeru nenamernega zaužitja takoj poiščite zdravniško pomoč in zdravniku pokažite navodila za uporabo ali ovojnino.
Semintra 4 mg/ml oral solution for cats Telmisartan
Semintra 4 mg/ml peroralna raztopina za mačke telmisartan
Semintra 10 mg/ml oral solution for cats
Semintra 10 mg/ml peroralna raztopina za mačke
Pack size of one bottle and one measuring syringe.
Velikost pakiranja je ena plastenka in ena merilna brizga.
The solution should be given using the measuring syringe provided in the package.
Raztopina se daje z merilno brizgo, ki je priložena pakiranju.